For nearly 25 years, James Kyle Bryan, M.D. has excelled in his career as a hematologist and oncologist. He brings that experience, along with drug development expertise working with both pharmaceutical companies and global CROs, to IQVIA Biotech. As Chief Medical Officer he provides strategic global medical and scientific leadership for medical, safety, feasibility, oncology strategy, and global strategic delivery teams as well as consulting services to sponsors regarding preclinical and clinical data, regulatory strategy, protocol design and drug development strategy. His guidance and expertise help ensure the safety of patients during the conduct of clinical trials.

Kyle has been fascinated by the science of clinical research since his first exposure to the workings of phase 1 trials. However, his greatest inspiration comes from his time at the bedside. “We work in an endlessly fascinating world of science, but if we lose sight of the patient or lose the ability to share the feelings of those most directly impacted by disease, then none of our accomplishments will amount to very much,” Kyle said. “It’s imperative that we all recognize that the patient is the essence of the entire complex, multifaceted world of clinical research. Every point of data in our studies represents a tiny piece of a life that is counting on people like us to make a difference. If we make this work about ourselves instead of about others, then we’ll never be truly successful.”

Prior to joining IQVIA Biotech, Kyle served as chief medical officer for VentiRx Pharmaceuticals in Seattle where he was responsible for moving immuno-oncology compounds into and through the clinical development process, including trial design and execution, clinical research, and data analysis. He has also served as vice president of medical affairs for Seattle Genetics, managing a national medical affairs team in coordination with clinical development and research groups. In this role he was responsible for overseeing the medical science liaison force, as well as directing the investigator-sponsored study and expanded access program, publication strategy, and medical information. Other previous roles include vice president of global drug development at a global CRO, and director of clinical research at NeoRx Corporation.

Kyle remains active clinically, holding an appointment as a clinical instructor for hematology and oncology at the University of Washington Medical Center and Harborview Medical Center. He was previously head of the division of hematology and oncology at Pacific Medical Center, where he was an investigator on institutional and cooperative group trials and helped develop institutional guidelines and medical training programs. He has developed evaluation and management algorithms for diseases including anemia, leukopenia, thrombocytopenia, bleeding, hypercoagulability, and others.

A distinguished writer, Kyle has co-authored more than 20 peer reviewed publications, including articles published in Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research. Recently, Kyle was honored by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry in the 2021 PharmaVOICE 100.

Kyle is an alumnus of Louisiana State University, where he received both his bachelor’s degree in biochemistry as well as his medical degree and served as clinical chief resident. He completed his fellowship in hematology and oncology at the University of Washington, and is board certified in medical oncology and hematology.

With clinical trial expertise stemming both from his time as a clinician and his experience in the pharmaceutical industry, Kyle brings a unique understanding of clinical research that benefits IQVIA Biotech and its customers. He resides in Seattle with his husband and two teenagers. He is an advocate for adoption and foster care, an art collector, and voracious reader.

Having an experienced medical team is critical to the success of your clinical development program. Contact us to learn how our medical and scientific insights can support your clinical research trial.